Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
October 30, 2024 - … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and …
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
October 29, 2024 - … of molecular glue drug discovery while prosecuting a pipeline of projects through clinical development. Neomorph … of, and expectations for, our commercial business and pipeline programs; capital allocation and investment … of molecular glue drug discovery while prosecuting a pipeline of projects through clinical development. Neomorph …
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
October 29, 2024 - … the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of … the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of … the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of …
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
October 28, 2024 - … the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of … the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of … the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of …
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
October 26, 2024 - … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated … of IgAN; the potential of our commercial business and pipeline programs, including felzartamab; and risks and … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated …
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
October 24, 2024 - … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and …
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
October 22, 2024 - … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated … IgAN and PMN; the potential of our commercial business and pipeline programs, including felzartamab; and risks and … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated …
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
October 16, 2024 - … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and … Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and …
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
October 9, 2024 - … of AMR; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and … of AMR; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and … of AMR; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and …
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
October 8, 2024 - … of SMA; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and … of SMA; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and … of SMA; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and …
